# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as...
Key Findings from the Phase 3 GBS Trial of ANX005 30 mg/kg Treatment Phase 3 trial informed by dose-ranging Phase 1b trial, ...
The pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the...
Cantor Fitzgerald analyst Pete Stavropoulos reiterates Annexon (NASDAQ:ANNX) with a Overweight.